Loading…
Loading…
RMTI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for RMTI and 80,000+ other tickers.
See exactly how RMTI's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RMTI and 80,000+ other tickers.
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients…
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #1049 at ASN Kidney Week 2026 at the Colorado Convention Center in Denver, CO.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--This marks the 3rd consecutive year that Rockwell Medical earned this recognition—climbing the ranks from #50 (2024) and #40 (2025) to #16 (2026).
Embecta (NASDAQ: EMBC - Get Free Report) and Rockwell Medical (NASDAQ: RMTI - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares Embecta and Rockwell Medical's
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript